Therapeutic

Currently, the most established technique for heart failure is heart transplantation, which has its own complications. There is a drastically increasing number of patients with heart failure every year, yet there is less availability of heart donors, and the possibility of acute and chronic rejection and using life-long immune suppressing drugs are just a few of the shortcomings associated with the current transplantation approach for treating patients with heart failure.

On one hand, Life Systems Corp is striving to improve organ transplantation techniques by improving organ preservation and increasing the pool of donor organs from non-heart beating donors. On the other hand, the Company is emphasizing its internal research activities on an alternative technique of using cell transplantation for treating patient with heart failure.

Currently, Life Systems Corp is in the process of negotiating the licensing of cell therapy treatment from several select accredited entities and has executed non-disclosure agreement with these
institutes, which it prevents the Company from disclosing any extensive details about these cell therapies for heart failure.

The cell therapy technique we anticipate developing uses cells for transplantation that are obtained from the patient's own body. This avoids the necessity of using immune suppressing drugs to prevent the possibility of acute or chronic rejection and also is completely free from moral hesitations associated with the use of embryonic stem.